? Daiichi Sankyo Company, Limited announced that it has launched DELYTACT? (teserpaturev/G47)*1, an oncolytic virus developed by the company in collaboration with Professor Tomoki Todo (hereinafter, Dr. Todo) of the Institute of Medical Science, The University of Tokyo. DELYTACT? received conditional and time-limited marketing approval in Japan as a regenerative medical product for treatment of malignant glioma in June 2021 based on results from a Japanese phase 2 clinical trial (investigator-initiated trial) in patients with glioblastoma*2 (a type of malignant glioma*3) conducted by Dr. Todo. For the time being, DELYTACT? will be commercially available only at hospitals that served as trial sites. Daiichi Sankyo will establish a stable supply system of the medicine as soon as possible. Daiichi Sankyo is pleased to offer DELYTACT? as a new option for the treatment of malignant glioma and to contribute to the high unmet medical needs of patients suffering from this brain cancer.